收藏切换
Long-term complete remission achieved by pembrolizumab for dMMR/MSI-H advanced colon cancer: a case report
收藏切换
Sheng-hui ZHANG1, Di WANG1, Shuai-hua CHENG1, Yang LIN1, Hong-ling LI2, *
Chinese Journal of New Drugs | 2026, 35(10) : 1108 - 1112
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(10): 1108-1112
Long-term complete remission achieved by pembrolizumab for dMMR/MSI-H advanced colon cancer: a case report
Full
Sheng-hui ZHANG1, Di WANG1, Shuai-hua CHENG1, Yang LIN1, Hong-ling LI2, *
Affiliations
  • 1The First Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China
  • 2Department of Medical Oncology, Gansu Provincial People's Hospital, Lanzhou 730000, China
Published: 2026-05-30 doi: 10.20251/j.cnki.1003-3734.2026.10.013
Outline
收藏切换

Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related deaths worldwide and has become a major threat to global health. In recent years, various screening and detection technologies have emerged; however, approximately 25% of CRC patients are still diagnosed at an advanced stage. Up to 50% of patients with initially localized disease develop metastases, and the 5-year survival rate for metastatic CRC remains below 15%. Furthermore, traditional treatments exhibit significant variability in response to molecularly heterogeneous tumors. Breakthroughs in immune checkpoint inhibitors (ICIs) have provided new treatment modalities for advanced CRC, particularly for patients with the microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) subtype. This report details the case of a 55-year-old man with dMMR/MSI-H advanced colorectal cancer (CRC). Following multiple prior treatment failures, the initiation of pembrolizumab led to rapid tumor shrinkage and a sustained decline in tumor markers. The patient attained complete remission (CR) after seven treatment cycles and achieved long-term survival, with a follow-up of five years. This case study explored the decision-making process in cancer diagnosis and treatment, thereby providing a valuable reference for clinical practice.

advanced colorectal cancer  /  dMMR/MSI-H  /  pembrolizumab  /  immunotherapy  /  lynch syndrome
张圣慧, 王迪, 成帅华, 蔺阳, 李红玲. 帕博利珠单抗治疗dMMR/MSI-H晚期结肠癌实现长期生存1例. 中国新药杂志, 2026 , 35 (10) : 1108 -1112 . DOI: 10.20251/j.cnki.1003-3734.2026.10.013
Sheng-hui ZHANG, Di WANG, Shuai-hua CHENG, Yang LIN, Hong-ling LI. Long-term complete remission achieved by pembrolizumab for dMMR/MSI-H advanced colon cancer: a case report[J]. Chinese Journal of New Drugs, 2026 , 35 (10) : 1108 -1112 . DOI: 10.20251/j.cnki.1003-3734.2026.10.013
Year 2026 volume 35 Issue 10
48
7
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.10.013
  • Online Date:2026-10-26
  • Published:2026-05-30
Article Data
Affiliations
History
  • Accepted:2025-10-14
Funding
Affiliations
    1The First Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China
    2Department of Medical Oncology, Gansu Provincial People's Hospital, Lanzhou 730000, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.10.013
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT